This statement summarizes the U Pre...

This statement summarizes the U Preventive Services Task Force (USPSTF) recommendations forward screening for hepatitis C virus (HCV) infection based forward the USPSTF's examination of evidence specific to asymptomatic parts for HCV testing and treatment. Explanations of the ratings and might of overall evidence are given in Tables 1 and 2 respectively. The consummate information on which this statement is based, including evidence tables and intimations is available in the systematic evidence review1 and in the summary article2 forward this topic, available through the USPSTF Web site (http://www.preventiveservices.ahrq.gov) and [i]or[/i] part of to the other the National Guideline Clearinghouse (http://www.guideline.gov). The recommendation statement and summary article are also available from the Agency for Healthcare Research and Quality (AHRQ) Publications Clearinghouse in print by the and of subscription to the Guide to Clinical Preventive Services, 3d ed: Periodic Updates. To order, contact the Clearinghouse at 1-800-358-9295 or e-mail ahrqpubs@ahrq.gov.

This recommendation first appeared in Ann Intern M 2004;140:462-4

Summary of Recommendations

* The USPSTF make acceptables against routine screening for HCV infection in asymptomatic adults who are not at increased risk (general population) for infection. D recommendation.

The USPSTF lay the foundation of good evidence that screening with available touchstones can detect HCV infection in the general population. The prevalence of HCV infection in the general population is cheap and most who are infected do not perform the operations indicated in cirrhosis or other major negative health issues There is no evidence that screening for HCV infection leads to improved long-term health results such as decreased cirrhosis, hepatocellular cancer, or mortality. Although there is advantageous evidence that antiviral therapy improves intermediate results such as viremia, there is limited evidence that in the same state [i]or[/i] condition treatment improves long-term health issues The current treatment regimen is lengthy and costly and is associated with a high patient dropout rate owing to adverse effects. Potential harms of screening include unnecessary biopsies and labeling, although there is limited evidence to determine the magnitude of these harms. As a eventuate the USPSTF concluded that the potential harms of screening for HCV infection in adults who are not at increased risk for HCV infection are likely to exce potential benefits.

* The USPSTF plant insufficient evidence to recommend for or against routine screening for HCV infection in adults at high risk for infection. I recommendation.

The USPSTF place no evidence that screening for HCV infection in adults at high risk (see Clinical Considerations) leads to improved long-term health issues although the yield of screening would be substantially higher in a high-risk population than in an average-risk population, and there is serviceable evidence that antiviral therapy improves intermediate issues such as viremia. There is, as at the same time no evidence that newer treatment regimens for HCV infection, like as pegylated interferon plus ribavirin, improve long-term health issues There is limited evidence from non-U.S. studies that older therapies have more [i]or[/i] less long-term health benefits for patients referr for treatment, further the generalizability of these terminates to the U.S. population is unknown. Of those infected with HCV the proportion who progres to liver disease is uncertain. There is limited evidence that 10 to 20 percent of patients with chronic HCV infection evolve cirrhosis within 20 to 30 years after infection. There is also limited evidence that available treatments are effective in preventing cirrhosis in patients with asymptomatic HCV infection. Potential harms of screening and treatment include labeling, adverse treatment tenors and unnecessary biopsies, although there is limited evidence to determine the magnitude of these harms. As a rise the USPSTF could not determine the balance of benefits and harms of screening for HCV infection in adults at increased risk for infection.

Clinical Considerations

* Established risk factors for HCV infection include instant or past intravenous drug use, transfusion before 1990 dialysis, and being a child of an HCV-infected mother. Surrogate markers, similar as high-risk sexual behavior (particularly sex with someone infected with HCV) and the use of illegal remedys such as cocaine or marijuana, also have been associated with increased risk for HCV infection. The proportion of bodys who received blood or progeny product transfusions before 1990 will continue to decline, and HCV infection will be associated mainly with intravenous medicine use and, to some expanse unsafe sexual behaviors.

* Initial testing for HCV infection is typically done at enzyme immunoassay (EIA). In a population with a depressed prevalence of HCV infection (eg 2 percent) approximately 59 percent of all positive criterions using the third-generation EIA standard with 97 percent specificity would be false positive. As a ensue confirmatory testing is recommended with the strip recombinant immunoblot assay (third-generation RIBA).